开发SRC-3抑制剂的化合物,具有改善的药理动力学特性和抗癌效率
Dong Lu1, Jianwei Chen1, Li Qin2
1Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.
Journal of medicinal chemistry
|March 29, 2024
概括
新的候选药物,SI-10和SI-12,显示强烈抑制类固醇受体辅激剂-3 (SRC-3) 并显著减少瘤生长和转移,毒性最小.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 类固醇受体协活性剂3 (SRC-3) 是癌细胞增殖和转移的关键调节剂.
- 准SRC-3为各种癌症提供了潜在的治疗策略.
研究的目的:
- 为了优化打击化合物 (SI-2) 增强抗癌活性和类似药物的特性.
- 确定用于癌症治疗的新型SRC-3抑制剂.
主要方法:
- 结构-活性关系 (SAR) 研究和SI-2的药物样优化.
- 在体外和体外代谢和细胞毒性测试.
- 使用生物化雌激素反应元素拉下测试的雌激素受体复合体分析.
主要成果:
- 发现了两种化合物,SI-10和SI-12,对人类癌症细胞系具有强烈的细胞毒性.
- SI-12证明了雌激素受体复合体中SRC-3和p300招募的干扰.
- 在体内,SI-10和SI-12显著抑制瘤生长和转移,没有显著的急性毒性.
结论:
- 由于它们具有强大的SRC-3抑制作用,SI-10和SI-12是癌症治疗的有希望的候选药物.
- 已识别的化合物具有有利的药理动力学和毒性概况,需要进一步的临床研究.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
7.4K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K